BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jul 05, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Contrave: Phase II data

In an open-label Phase II trial in 23 overweight or obese patients with major depressive disorder (MDD), Contrave (32 mg naltrexone SR/360 mg bupropion SR) significantly reduced mean MADRS total score from 23.7 points at baseline to 10.5 and 8.4 points at weeks 12 and 24,...

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >